ATAI
Ataibeckley Inc.
A clinical-stage biopharmaceutical company developing psychedelic-inspired treatments for mental health, including BPL-003, a short-acting nasal spray for hard-to-treat depression. It was born in 2025 from the merger of atai Life Sciences and Beckley Psytech, the latter named after Beckley Park, the centuries-old English estate of the Feilding family. Its lead therapy is a synthetic form of a compound found in toad venom.
CINS: N0731H1031 holder
Dec 30, 2025 — Reclassified as Atai Beckley NV (1:1)
Total Value
$10.68M
Total Shares
2.02M
Net Share Change
+2.02M
Activity
1 buying
Investor
Value
Shares
Weight
Change
